Loading

Teva comes out on top with $5B Ratiopharm bid

And the winner is… Teva. This morning, the generics giant announced that it was buying Ratiopharm for just under $5 billion, beating out Pfizer and Actavis for the German company.

Add this post to your favorites social bookmark

Bookmark and Share